Targeting iron-metabolism:a potential therapeutic strategy for pulmonary fibrosis

Biomed Pharmacother. 2024 Mar:172:116270. doi: 10.1016/j.biopha.2024.116270. Epub 2024 Feb 15.

Abstract

Iron homeostasisis is integral to normal physiological and biochemical processes of lungs. The maintenance of iron homeostasis involves the process of intake, storage and output, dependening on iron-regulated protein/iron response element system to operate tightly metabolism-related genes, including TFR1, DMT1, Fth, and FPN. Dysregulation of iron can lead to iron overload, which increases the virulence of microbial colonisers and the occurrence of oxidative stress, causing alveolar epithelial cells to undergo necrosis and apoptosis, and form extracellular matrix. Accumulated iron drive iron-dependent ferroptosis to exacerbated pulmonary fibrosis. Notably, the iron chelator deferoxamine and the lipophilic antioxidant ferritin-1 have been shown to attenuate ferroptosis and inhibit lipid peroxidation in pulmonary fibrosis. The paper summarises the regulatory mechanisms of dysregulated iron metabolism and ferroptosis in the development of pulmonary fibrosis. Targeting iron metabolism may be a potential therapeutic strategy for the prevention and treatment of pulmonary fibrosis.

Keywords: Alveolar epithelial cells; Ferroptosis; Fibroblast; Iron metabolism; Macrophage; Pulmonary fibrosis.

Publication types

  • Review

MeSH terms

  • Alveolar Epithelial Cells
  • Humans
  • Iron
  • Lipid Peroxidation
  • Oxidative Stress
  • Pulmonary Fibrosis* / drug therapy

Substances

  • Iron